Antibody drug conjugate ado trastuzumab emtansine: An updated review / 国际药学研究杂志
Journal of International Pharmaceutical Research
;
(6): 665-669, 2016.
Article
in Chinese
| WPRIM
| ID: wpr-845511
ABSTRACT
As a new design strategy of anticancer drugs, antibody-drug conjugates have become a research hotspot in recent years. In 2013, the successful launch of ado trastuzumab emtansine(Kadcyla) provided a new solution for second-line treatment with trastuzumab-resistant HER2-positive advanced breast cancer patients. Based on its excellent clinical performance and HER2‘s overexpressing in many tumors, Roche further attempts to expand it for the therapy of HER2-positive metastatic breast cancer of each line and neoadjuvant for early breast cancer treatment, as well as applications to gastric cancer and non-small cell lung cancer(NSCLC) treatment. In general, results are mixed. Its position as second-line drugs of is further established, but factors such as tumor heterogeneity are still a big challenge. This paper reviews the recent progress in these areas after its launch.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Journal of International Pharmaceutical Research
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS